Phaseline

Companies › Taejoon Pharmaceutical

Taejoon Pharmaceutical: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 3; Ophthalmology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CTO0308
Ophthalmic myopia progression inhibitor
–Phase 3MyopiaApr 2027
TJO-087–Phase 2Dry Eye Syndrome (DES)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07810972TJO-087Phase 2Dry Eye Syndrome (DES)OphthalmologyDec 2026
NCT07790640CTO0308Phase 3MyopiaOphthalmologyApr 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Huons Andover Research Eye Institute SANGMYUNG innovation Vantage Biosciences Tourmaline Bio, Inc., a Novartis Company

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.